• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Crinone 8%
    / Merck Serono LTD, Israel

    Active Ingredient
    Progesterone 8% w/w

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    15 X 1.45 g

    partial basket chart 58548 3745


    Intravaginal application.
    Treatment of infertility due to inadequate luteal phase: One application (1.125 g 8% gel) every day, starting after documented ovulation or arbitrarily on the 18th-21st day of the cycle.
    Use during in-vitro fertilization: Daily application of Crinone 8% gel should be continued for 30 days if there is laboratory evidence of pregnancy.
    Paediatric population: Not applicable.
    Older people: Not applicable.
    Method of Administration: Crinone is applied directly from the specially designed sealed applicator into the vagina. The applicator should be removed from the sealed wrapper. The twist-off cap should not be removed at this time.
    1. The applicator should be gripped firmly by the thick end. It should be shaken down like a thermometer to ensure that the contents are at the thin end.
    2. The tab should be twisted off and discarded.
    3. The applicator may be inserted while patient is in a sitting position or when lying on her back with the knees bent. The thin end of applicator should be gently inserted well into the vagina.
    4. The thick end of the applicator should be pressed firmly to deposit gel. The applicator should be removed and discarded in a waste container.


    – Treatment of infertility due to inadequate luteal phase.
    – For use during in-vitro fertilization, where infertility is mainly due to tubal, idiopathic or endometriosis linked sterility associated with normal ovulatory cycles.


    -Hypersensitivity to the active substance or to any of the excipients. See prescribing information for full details.
    -Undiagnosed vaginal bleeding.
    -Known or suspected progesterone-sensitive malignant tumors.
    -Thrombophlebitis, thromboembolic disorder, cerebral apoplexy, or patients with a history of these conditions.
    -Missed abortion.

    Special Precautions

    – The pre-treatment physical examination should include special reference to breast and pelvic organs, as well as Papanicolaou smear.
    – Cautious use in severe hepatic insufficiency.
    – In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, non-functional causes should be considered. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures should be undertaken.
    – This medicinal product is not indicated in threatened abortion. Treatment should be discontinued in the event of a missed abortion.
    – The physician should be alert to the early manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorder, pulmonary embolism and retinal thrombosis). Should any of these symptoms occur or be suspected, the drug should be discontinued immediately. Patients who have risk factors for thrombotic disorders should be kept under careful observation.
    – Although risk of thromboembolism has been associated with estrogens, a link with progestins remains questionable. Therefore, in women with generally recognised risk factors for thrombo-embolic events, such as personal or family history, treatment with this product may further increase the risk. In these women, the benefits of treatment need to be weighed against the risks. It should be noted however, that pregnancy itself carries an increased risk of thrombo-embolic events.
    – Because progestogens may cause some degree of fluid retention, conditions that might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
    – Patients who have a history of depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
    – A decrease in glucose tolerance has been observed in a small number of patients on oestrogen-progestin combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.
    – The excipient sorbic acid may cause local skin reactions (e.g. contact dermatitis) or vaginal irritation.

    Side Effects

    This medicinal product is generally well tolerated. Most adverse events observed in clinical studies cannot be distinguished from the symptoms common in early pregnancy.
    Common: Breast tenderness, itching or burning.
    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    Ares trading, Switzerland